Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy View Full Press Release Travere Therapeutics to Report First Quarter 2025 Financial Results Travere Therapeutics Reports First Quarter 2025 Financial Results